As anticipated, the GPR160 protein levels on POD 18 were notably diminished in the ipsilateral DRG of rats subjected to AAV2/9-Gpr160 shRNA microinjections conducted 28 and 16 days prior to tumor cell injection, in comparison to those microinjected with AAV2/9-Scr shRNA (Fig. EV3D–G). Here, GPR160 is linked to neoplasm.